Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10244583 | 0.93 | ADRB2 (0.52) | MCHR1ADRB2MTNR1BALDH1A1KCNH2 | |
| SCHEMBL327335 | 0.86 | MCHR1 (0.67) | MCHR1ADRB2MTNR1BALDH1A1KCNH2 | |
| SCHEMBL10190094 | 0.86 | MCHR1 (0.59) | MCHR1ADRB2MTNR1BALDH1A1KCNH2 | |
| SCHEMBL10190100 | 0.78 | ADRB2 (0.53) | MCHR1ADRB2MTNR1BALDH1A1KCNH2 | |
| SCHEMBL321217 | 0.76 | ADRB2 (0.56) | MCHR1ADRB2MTNR1BALDH1A1KCNH2 | |
| SCHEMBL322065 | 0.76 | MCHR1 (0.52) | MCHR1ADRB2MTNR1BALDH1A1KDM4E | |
| SCHEMBL322333 | 0.75 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL321388 | 0.75 | MCHR1 (1.00) | MCHR1KCNH2HRH3 | |
| SCHEMBL10264311 | 0.74 | MCHR1 (0.89) | MCHR1KCNH2HRH3 | |
| SCHEMBL326893 | 0.74 | MCHR1 (0.63) | MCHR1ADRB2MTNR1BALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | TYR, MC2R, MC1R | MCHR1 9/4885ADRB2 184/4885MTNR1B 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.